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Down-modulation of the C/EBP␣ transcription factor in core binding factor acute myeloid leukemias
Acute myeloid leukemia (AML) is characterized by abnormalities frequently affecting transcriptional control elements, leading to differentiation block. 1 C/EBP␣ is one of the most frequently involved transcription factors, being disrupted by point mutations in 7% to 11% of cases. [2] [3] In the setting of the t(8;21) AML, C/EBP␣ function has been shown to be downregulated by the AML-ETO fusion protein. 4 The latter mechanism was reported as a peculiarity of t(8;21)-positive AML, apparently not shared by other subtypes. 4 Using a quantitative real-time polymerase chain reaction (RQ-PCR) method, 5, 6 we analyzed the C/EBP␣ expression levels in 144 bone marrows (BMs) (16) positive. C/EBP␣ expression was also tested in serial samples from 18 patients during follow-up (7 characterized by t(8;21), 5 by inv(16), and 6 by a normal karyotype).
As shown in Figure 1A , we detected a significant down-modulation of C/EBP␣ transcript in the samples positive for the presence of the t(8,21) and inv(16) cytogenetic abnormalities with respect to the other types of AMLs (mean value of C/EBP␣ copies/10 4 ABL copies: 33 638 vs 77 813, P ϭ .0001), which showed values similar to those found in healthy controls (77 865 and 56 845 C/EBP␣ copies/10 4 ABL copies in normal BM and PB, respectively). Moreover, the comparison between the C/EBP␣ values obtained in BM samples from patients with AML1/ETO-positive FAB M 2 AML compared with AML1/ETOnegative FAB M 2 cases demonstrated a highly significant difference (32 523 vs 71 985 C/EBP␣ copies/10 4 ABL copies, P ϭ .0001). Similar differences were detected by analyzing FAB M 4 cases with and without the CBFb/MYH11 fusion (35 644 vs 105 173 C/EBP␣ copies/10 4 ABL copies, P ϭ .0002). The Western blot assays further confirmed these data by showing a reduction of the total amount of C/EBP␣ protein in AML cases with t(8;21) or inv(16) with respect to those lacking these abnormalities. A further demonstration that the down-regulation of C/EBP␣ is a characteristic feature of the CBF-disrupted AMLs derives from data obtained on follow-up samples ( Figure 1B) . In patients characterized by t(8;21) and inv(16) (7 and 5, respectively) who achieved a complete remission (CR), C/EBP␣ transcript amounts increased to values not significantly different from those obtained in normal samples (P ϭ .4) or in the other subgroups of AML at onset (P ϭ .2). Subsequently, these values remained stable in all of the samples collected during CR, and showed a significant decrease in 3 cases of t(8;21) and in 1 case of inv(16) who subsequently relapsed. By contrast, the 6 patients with normal karyotype did not show significant differences between the CEBP␣ expression level at onset, in CR, and at relapse.
Our data clearly show that decreased levels of C/EBP␣ expression are present also in the AML cases with inv(16) and, therefore, that down-modulation of C/EBP␣ is a common feature of both major subtypes of CBF AMLs (ie, t(8;21)-positive and inv(16)-positive AML).
